Epilepsy with partial and/or generalized seizures
Conditions
Interventions
Trade Name: Keppra 500mg
Product Name: Levetiracetam
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: levetiracetam
CAS Number: 102767-28-2
Current Sponsor code: ucb-L059
Concentration u
Sponsors
Hospital Ruber Internacional
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: -Subjects are informed and have given their written informed consent -Subjects between 16 and 55 years of age -Subjects have a diagnosis of epilepsy with partial and/or generalized seizures according to the International Clasification of Epileptic Seizures (1989) -Subjects who are going to start on a monotherapy regimen of levetiracetam Are the trial subjects under 18? yes Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: -Subject with a progressive structural lesion in the central nervous system or progressive encephalopathy. -Subject has any other clinically significant disease, surgical condition that might reasonably influence central nervous system function.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To analyse variations of gamma band power in epileptic patients before and after having levetiracetam. ;Secondary Objective: Determine different profiles of gamma activity between different epilepsy types and validate MEG for evaluating memory in epileptic patients.;Primary end point(s): Gamma band activity measured with MEG and seizure frequency. | — |
Countries
Spain
Outcome results
None listed